Complications of diabetes therapy

Endocrinol Metab Clin North Am. 2013 Dec;42(4):947-70. doi: 10.1016/j.ecl.2013.06.005. Epub 2013 Aug 12.

Abstract

Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks. Maintaining glycemic control over time is a significant challenge because of the progressive nature of diabetes as a result of declining β-cell function. This article identifies complications of non-insulin treatments for diabetes. The major classes of medications are reviewed with special focus on target population, mechanism of action, effect on weight, cardiovascular outcomes and additional class-specific side effects including effects on bone. Effects on β-cell function are also highlighted.

Keywords: Cardiovascular outcomes; Diabetes; Treatment complications; β-cell function.

Publication types

  • Review

MeSH terms

  • Biguanides / adverse effects
  • Biguanides / therapeutic use
  • Diabetes Mellitus, Type 2 / therapy*
  • Glucagon-Like Peptide 1 / adverse effects
  • Glucagon-Like Peptide 1 / analogs & derivatives
  • Glucagon-Like Peptide 1 / therapeutic use
  • Glycoside Hydrolase Inhibitors
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Resistance
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / pathology
  • Islet Amyloid Polypeptide / adverse effects
  • Islet Amyloid Polypeptide / therapeutic use
  • Sulfonylurea Compounds / adverse effects
  • Sulfonylurea Compounds / therapeutic use
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / therapeutic use

Substances

  • Biguanides
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • Islet Amyloid Polypeptide
  • Sulfonylurea Compounds
  • Thiazolidinediones
  • Glucagon-Like Peptide 1